Form 4: Mangoceuticals Director D'Alessio Reports Stock Award and Disposal

Director Lorraine Pamela D'Alessio reports acquisition of 25,000 shares of Mangoceuticals stock as a bonus and disposal of 36,667 shares.

Summary

• On April 10, 2025, Lorraine Pamela D'Alessio, a director of Mangoceuticals, Inc. (MGRX), reported a transaction involving the company's common stock.
• D'Alessio acquired 25,000 shares as a discretionary bonus for services rendered as a board member, issued under the company's 2022 Equity Incentive Plan.
• The acquisition was exempt pursuant to Rule 16b-3.
• D'Alessio also disposed of 36,667 shares.
• Following these transactions, D'Alessio's beneficial ownership of Mangoceuticals stock is not explicitly stated in the provided document.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without providing significant positive or negative indicators. The disposal of shares tempers the positive aspect of the bonus.

Positives

• The acquisition of shares by a director, even as a bonus, could be seen as a positive sign of alignment with shareholder interests.

Negatives

• The disposal of 36,667 shares by the director could be interpreted negatively by investors.

Risks

• The document does not provide enough context to fully assess the implications of the stock disposal.
• Without knowing the reasons behind the disposal, it's difficult to determine if it signals any concerns about the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The market's reaction to such filings often depends on the size and nature of the transactions, as well as the overall sentiment surrounding the company.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions could affect employee morale depending on their perception of insider confidence in the company.

Key Dates

Keywords

Mangoceuticals, MGRX, Director, D'Alessio, Stock, Bonus, Acquisition, Disposal, Equity Incentive Plan, Beneficial Ownership